The United Kingdom (UK) and the Netherlands have only approved GLP-1s for people with BMIs above 30 and 35, respectively
When the patent expires in March 2026, the supply chain localizes
CT-measured visceral fat fell about 15% over 26 weeks in Phase III trials, with the change reversing within about 26 weeks after stopping
Based on these findings, it seems that someone in the world of pathology should do a histological study exposing kidneys to lithium and then exposing a set to a placebo and the other to a GLP-1 agent and seeing if we can get molecular cellular protection. Conducting a randomized controlled trial to investigate the protective role of GLP-1 RAs is challenging, but perhaps we could rely on observational studies supported by this type of mechanistic study, which could move the needle on potential clinical implications [of our findings], Dr McIntrye said
Faster recovery Exercise, illness, alcohol, and poor sleep all create oxidative stress
A large cohort study of 461,382 GLP-1 users found that 12.7% of patients had a new nutritional deficiency diagnosis at just 6 months of therapy